Added benefit of Invokana in type 2 diabetes is not proven, says IQWiG

17 June 2014

In an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) now examined whether canagliflozin alone (monotherapy) or in combination with other blood-glucose lowering drugs offers an added benefit over the appropriate comparator therapy.

No added benefit can be derived from the dossier, however, because the manufacturer did not present any suitable data for any of the possible therapeutic indications, the IQWiG stated.

US health care giant Johnson & Johnson (NYSE: JNJ) subsidiary Janssen-Cilag gained marketing authorization for its Invokana (canagliflozin) last year as monotherapy and in various combination therapies for adults with type 2 diabetes mellitus when diet and exercise alone do not provide adequate glycemic control.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK